Trial · NCT00306150
Registered outcomes12
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 12 of 12
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | The primary criterion for efficacy is the percent of patients requiring a blood transfusion anytime in the intra-operative or post-operative period (up to the earlier of Day 7 or discharge) | Anytime in the intra-operative or post-operative period (up to the earlier of Day 7 or discharge) | |
| Secondary | The number of units of blood or packed red cells transfused. There will be an analysis for the combination of autologous and allogenic transfusion and for allogenic alone | Intra- and postoperative | |
| Secondary | The number of units of blood or packed red cells transfused per patient requiring transfusion | Intra- and postoperative | |
| Secondary | The intraoperative blood loss determined as follow: a) by surgeon estimate b) summing weight of the blood in gauze and other materials and the suction drainage volume | Intraoperative | |
| Secondary | The drainage volume (in milliliters) from the operative site | In the first 8 hours post-operatively, and daily total drainage until removal of drains or until discharge, whichever comes first | |
| Secondary | Transfusion of platelets, colloids, plasma and number of patients requiring these products | Intra- and postoperative | |
| Secondary | The change from preoperative hemoglobin concentration to postoperative hemoglobin concentration | Obtained in the morning of postoperative Day 3, or, if transfused earlier, prior to transfusion | |
| Secondary | Surgeon s assessment of the degree to which bleeding obscures his/her view of the surgical field, relative to past, similar procedures | Intraoperative | |
| Secondary | Changes in blood markers related to inflammation and blood coagulation; baseline until Discharge or day 7 | Several measurements from baseline up to 6 weeks | |
| Secondary | Time to discontinuing of mechanical ventilation | Not specifed | |
| Secondary | Changes in FEV1 | Baseline until Discharge or day7 | |
| Secondary | Changes in the patients health related quality of life (HRQoL) (at baseline and 6+-2 weeks post surgery) using the Functional Assessment Cancer Therapy for patients with Bladder cancer (FACT-Bl) questionnaire | At baseline and 6+-2 weeks post surgery |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00306150/registered